Development of reliable methods supporting adjunctive therapy for congenital heart surgery

Pediatric Critical Care Medicine

Volumn 10, Issue 3, 2009, Pages 410-412

  Zimmerman, Jerry J ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary bypass; Children; Corticosteroids; Modified ultrafiltration; Postoperative complications; Reliable methods; Standard work

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; ANTIINFLAMMATORY AGENT;

CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DRUG EFFECT; DRUG MEGADOSE; EDITORIAL; HEALTH SURVEY; HEART SURGERY; HUMAN; HYPERGLYCEMIA; PRIORITY JOURNAL; SURGICAL RISK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; CHILD; CONGENITAL HEART MALFORMATION; NOTE; REPRODUCIBILITY;

ANTI-INFLAMMATORY AGENTS; CHILD; HEART DEFECTS, CONGENITAL; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 68849100199     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e31819adeab     Document Type: Editorial

References (27)

1. Ohno T: Toyota Production System: Beyond Large-Scale Production. Portland, OR, Productivity Press, 1988
2. Allen M, Sundararajan S, Pathan N, et al: Anti-inflammatory modalities: Their current use in pediatric cardiac surgery in the United Kingdom and Ireland. Pediatr Crit Care Med 2009; 10:341-345
3. Checchia PA, Bronicki RA, Costello JM, et al: Steroid use before pediatric cardiac operations using cardiopulmonary bypass: An international survey of 36 centers. Pediatr Crit Care Med 2005; 6:441-444
4. Chaney MA: Corticosteroids and cardiopulmonary bypass: A review of clinical investigations. Chest 2002; 121:921-931
5. Replogle RL, Gazzaniga AB, Gross RE: Use of corticosteroids during cardiopulmonary bypass: Possible lysosome stabilization. Circulation 1966; 33:I86-I92
6. Chenoweth DE, Cooper SW, Hugli TE, et al: Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304:497-503
7. Kirklin JK, Westaby S, Blackstone EH, et al: Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86:845-857
8. Hammerschmidt DE: Leukocytes in lung injury. Chest 1983; 83:16S-20S.
9. Engelman RM, Rousou JA, Flack JE, III, et al: Influence of steroids on complement and cy-tokine generation after cardiopulmonary bypass. Ann Thorac Surg 1995; 60:801-804
10. Gessler P, Hohl V, Carrel T, et al: Administration of steroids in pediatric cardiac surgery: Impact on clinical outcome and systemic inflammatory response. Pediatr Cardiol 2005; 26:595-600
11. Millar AB, Armstrong L, van der Linden J, et al: Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Ann Thorac Surg 1993; 56:1499-1502
12. Berdat PA, Eichenberger E, Ebell J, et al: Elimination of proinflammatory cytokines in pediatric cardiac surgery: Analysis of ultrafil-tration method and filter type. J Thorac Cardiovasc Surg 2004; 127:1688-1696 (Pubitemid 38725449)
13. Lindberg L, Forsell C, Jogi P, et al: Effects of dexamethasone on clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen after paediatric cardiac surgery. Br J Anaesth 2003; 90:728-732
14. Sason-Ton Y, Ben Abraham R, Lotan D, et al: Tumor necrosis factor and clinical and metabolic courses after cardiac surgery in children. J Thorac Cardiovasc Surg 2002; 124: 991-998
15. Chaturvedi RR, Shore DF, White PA, et al: Modified ultrafiltration improves global left ventricular systolic function after open-heart surgery in infants and children. Eur J Car-diothorac Surg 1999; 15:742-746
16. Hennein HA, Kiziltepe U, Barst S, et al: Veno-venous modified ultrafiltration after cardiopulmonary bypass in children: A prospective randomized study. J Thorac Cardiovasc Surg 1999; 117:496-505
17. Davies MJ, Nguyen K, Gaynor JW, et al: Mod-ified ultrafiltration improves left ventricular systolic function in infants after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998; 115:361-369; discussion 369-370
18. Wang MJ, Chiu IS, Hsu CM, et al: Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operations. Ann Thorac Surg 1996; 61:651-656
19. Huang H, Yao T, Wang W, et al: Continuous ultrafiltration attenuates the pulmonary injury that follows open heart surgery with cardiopulmonary bypass. Ann Thorac Surg 2003; 76:136-140 (Pubitemid 36819729)
20. Rivera ES, Kimball TR, Bailey WW, et al: Effect of veno-venous ultrafiltration on myo-cardial performance immediately after cardiac surgery in children. A prospective randomized study. J Am Coll Cardiol 1998; 32: 766-772
21. Koutlas TC, Gaynor JW, Nicolson SC, et al: Modified ultrafiltration reduces postoperative morbidity after cavopulmonary connection. Ann Thorac Surg 1997; 64:37- 42; discussion 43
22. Draaisma AM, Hazekamp MG, Frank M, et al: Modified ultrafiltration after cardiopulmonary bypass in pediatric cardiac surgery. Ann Thorac Surg 1997; 64:521-525
23. Checchia PA, Backer CL, Bronicki RA, et al: Dexamethasone reduces postoperative tropo-nin levels in children undergoing cardiopulmonary bypass. Crit Care Med 2003; 31: 1742-1745
24. Bronicki RA, Backer CL, Baden HP, et al: Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 2000; 69:1490-1495
25. Schroeder VA, Pearl JM, Schwartz SM, et al: Combined steroid treatment for congenital heart surgery improves oxygen delivery and reduces postbypass inflammatory mediator expression. Circulation 2003; 107:2823-2828
26. Robertson-Malt S, Afrane B, El Barbary M: Prophylactic steroids for pediatric open heart surgery. Cochrane Database Syst Rev 2007; CD005550
27. Nadel S, Goldstein B, Williams MD, et al: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III ran-domised controlled trial. Lancet 2007; 369: 836-843